Loading
A phase 3 trial of Petosemtamab, Cetuximab, Bevacizumab in colorectal cancer, run by Genmab, now recruiting.
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) is a phase 3 interventional study registered as NCT07775287 by Genmab, with 600 participants planned, started 2026-09-15 and due to reach its primary completion in 2029-03-30. Interventions recorded: Petosemtamab, Cetuximab, Bevacizumab, 5-FU, Leucovorin (Calcium Folinate). Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Leucovorin (folinic acid), Cetuximab, Bispecific antibodies, Bevacizumab.
Shares Petosemtamab, Genmab, Cetuximab, Bispecific antibodies.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU), Bevacizumab, Anti-angiogenic therapy.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Cetuximab, Bevacizumab, Anti-angiogenic therapy.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU), Bevacizumab, Anti-angiogenic therapy.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Leucovorin (folinic acid), Fluorouracil (5-FU), Colorectal cancer.
Shares Petosemtamab, Genmab, Bispecific antibodies, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/